Who are the leading synbio investors?

This blog post has been written by the person who has mapped the synthetic biology market in a clean and beautiful presentation

The synthetic biology investment landscape reached $12.2 billion in venture funding during 2024, marking a significant recovery from the 2022-2023 downturn.

This comprehensive analysis reveals how Flagship Pioneering leads the space while Indie.Bio maintains the highest deal count, with AI-enabled platforms attracting the largest funding rounds and corporate venture capital arms increasingly participating across pharmaceuticals, agriculture, and industrial biotechnology sectors.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Get a Clear, Visual
Overview of This Market

We've already structured this market in a clean, concise, and up-to-date presentation. If you don't have time to waste digging around, download it now.

DOWNLOAD THE DECK

Who are the most active and influential investors in the synthetic biology space right now?

Flagship Pioneering dominates as the most influential synthetic biology investor, having created Moderna and continuing to build biotech companies solving industrial and environmental challenges through their venture creation model.

Indie.Bio leads in deal volume with 14 synthetic biology investments, operating as a San Francisco-based accelerator that provides $250K-$500K plus lab space and mentorship for 8% equity. Their portfolio spans Clara Foods (synthetic egg whites), Genesis DNA (gene synthesis), and Perfect Day (animal-free milk production).

Y Combinator has emerged as a significant player through multiple investments in genetic sequencing startups, research platforms, and drug discovery companies. OrbiMed manages over $18 billion in assets while expanding into biomaterials and bio-based chemicals, and Atlas Venture specializes in synthetic biology, microbial engineering, and bio-based industrial applications.

Tech titans provide substantial individual backing, with Bill Gates investing through the Gates Foundation, Eric Schmidt making significant synthetic biology bets, Peter Thiel backing multiple synbio companies, Marc Andreessen investing via Andreessen Horowitz, and Vinod Khosla supporting companies like LanzaTech and Calysta through Khosla Ventures.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Which synthetic biology startups have these investors backed, and what exactly do these startups do?

Ginkgo Bioworks represents the flagship synthetic biology platform, operating as the "organism company" that designs and programs custom cells across healthcare, agriculture, and materials with recent partnerships including $490M with Merck for biologics manufacturing optimization, $331M with Pfizer, and $406M with Boehringer Ingelheim.

Twist Bioscience leads DNA synthesis using silicon-based platforms, achieving $313 million in fiscal 2024 revenue with 28% year-over-year growth across synthetic biology ($123.5M), next-generation sequencing ($169.1M), and biopharma solutions ($20.3M). Amyris focuses on sustainable ingredient manufacturing, converting plant sugars into bioidentical molecules for skincare, sweeteners, medications, and fragrances, generating $269.8 million in 2022 revenue.

Mammoth Biosciences develops CRISPR-based diagnostic tools, LanzaTech converts carbon emissions to biofuels, Bolt Threads creates sustainable fashion materials from mycelium, Perfect Day produces animal-free dairy proteins, and Joyn Bio operates as a Ginkgo-Bayer joint venture developing nitrogen-fixing microbes for agriculture.

Generate Biomedicines secured $273 million in Series C funding for their generative biology platform that uses AI to design novel proteins and therapeutics. Asimov raised $175 million in Series B for cell programming tools that enable precise genetic circuit design, while Metagenomi obtained $100 million in Series B for gene editing therapeutics with reduced immune response.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

How much capital have these investors committed to each of these companies or across their synbio portfolio?

Major 2024 funding rounds demonstrate escalating investment levels, with Generate Biomedicines leading at $273 million Series C, followed by Asimov's $175 million Series B and Atlas Data Storage's $155 million seed round as a Twist Bioscience spinoff focused on DNA-based data storage.

Typical deal characteristics show clear stage progression: seed rounds range $250K-$3M (exemplified by Indie.Bio's model), Series A rounds span $10M-$50M, Series B rounds reach $50M-$200M, and Series C+ rounds exceed $200M for scaling and commercialization. The average investment per deal stabilizes around $5 million since 2020.

Flagship Pioneering's portfolio approach involves creating companies rather than traditional investing, with substantial commitments to ventures like Moderna (pre-IPO) and ongoing biotech creation. Corporate venture arms like AbbVie Ventures deploy 6-8 investments annually, typically focusing on seed and Series A rounds in oncology, immunology, and neuroscience applications.

Individual tech titans make investments ranging from $10M to $100M+ per company, with Bill Gates focusing on global health applications, Peter Thiel backing transformative platforms, and Vinod Khosla supporting bio-based chemicals and renewable energy companies through dedicated venture capital deployment.

What were the funding stages, deal sizes, and conditions typically associated with these investments?

Seed stage investments typically range $250K-$3M, with accelerators like Indie.Bio providing standardized packages of $250K-$500K plus lab access and mentorship in exchange for 8% equity stakes.

Series A rounds span $10M-$50M and focus on proof-of-concept validation, platform development, and initial commercial applications. Constructive Bio's $58 million Series A for synthetic genomics exemplifies the higher end of this range, targeting companies with demonstrated technical capabilities and clear market applications.

Series B funding reaches $50M-$200M for companies scaling their platforms and expanding applications across multiple verticals. Asimov's $175 million Series B for cell programming tools and Metagenomi's $100 million Series B for gene editing therapeutics represent typical scaling investments that enable commercial partnerships and expanded R&D capabilities.

Series C+ rounds exceed $200M and target companies preparing for commercialization, strategic partnerships, or public offerings. Generate Biomedicines' $273 million Series C demonstrates investor confidence in AI-powered drug design platforms that can accelerate traditional pharmaceutical development timelines while reducing costs.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

The Market Pitch
Without the Noise

We have prepared a clean, beautiful and structured summary of this market, ideal if you want to get smart fast, or present it clearly.

DOWNLOAD

Which countries or regions are seeing the most synbio investment activity, and why?

The United States dominates with 41.98% of global market share, driven by robust public-private funding ecosystems, leading universities and research institutions, supportive regulatory environments, and the presence of major platforms like Ginkgo Bioworks, Illumina, and Thermo Fisher Scientific.

Boston/Cambridge serves as the primary hub with Flagship Pioneering and Ginkgo Bioworks anchoring the ecosystem, while San Francisco Bay Area hosts Indie.Bio and numerous startups, and San Diego clusters around Twist Bioscience and established life sciences infrastructure. This geographic concentration creates network effects that accelerate innovation and funding cycles.

Asia-Pacific experiences the fastest growth with projected 24.9% CAGR, led by China's government backing of domestic pharmaceutical industry and aging population driving healthcare demand. Japan shows rising demand for gene therapies with major corporate investments, South Korea focuses on industrial biotechnology applications, and India benefits from government biofuel mandates and growing biotech sectors.

China demonstrates particular strength with major investments from Hillhouse Capital and Sherpa Healthcare Partners in companies like Leadsynbio (over $400M Series C). Australia invested $363 million across 17 synthetic biology companies over three years, while Europe shows positive investment trends with both European and non-European funds actively participating, particularly in the UK, Germany, Netherlands, and France.

Are major industry players backing synbio companies directly or via CVC arms?

Pharmaceutical companies primarily invest through dedicated corporate venture capital arms, with AbbVie Ventures deploying 6-8 investments annually focusing on seed and Series A rounds in oncology, immunology, and neuroscience applications.

Industry Sector	Key CVC Arms	Investment Focus Areas
Pharmaceuticals	AbbVie Ventures, Astellas Venture Management, J&J Innovation, Novartis Venture Fund, Pfizer Ventures	Pre-clinical cutting-edge science, biologics manufacturing, drug discovery platforms, therapeutic applications
Chemicals & Materials	BASF Venture Capital, DSM Investments, Merck KGaA M Ventures	Bio-based chemicals, sustainable materials, industrial biotechnology, 3D printing technologies
Agriculture	Bayer Leaps, Cargill Ventures, ADM Capital, Syngenta Ventures, Corteva VC	Crop enhancement, nitrogen-fixing microbes, agricultural biotechnology, sustainable farming
Energy	Shell Ventures, BP Ventures, ExxonMobil Technology Ventures	Biofuels, carbon capture utilization, renewable energy, bio-based chemicals
Industrial	GE Ventures, Honeywell Ventures, 3M New Ventures	Biomanufacturing automation, sustainable materials, industrial processes
Food & Consumer	Unilever Ventures, Nestle Ventures, Danone Manifesto Ventures	Alternative proteins, sustainable ingredients, food technology, consumer applications
Technology	Google Ventures, Microsoft M12, Intel Capital	AI-bio convergence, computational platforms, automation technologies, data analytics

If you want to build or invest on this market, you can download our latest market pitch deck here

What specific technologies, applications, or R&D breakthroughs are attracting the most investor attention right now?

AI and computational biology convergence represents the fastest-growing investment area, with the AI in synthetic biology market reaching $94.73 million in 2024 and projected to hit $438.37 million by 2034 at 16.56% CAGR.

Protein design and engineering using AlphaFold and similar models attracts substantial funding, enabling companies like Generate Biomedicines to raise $273 million for AI-powered drug design. Metabolic pathway optimization through machine learning accelerates organism design cycles, while automated design-build-test-learn cycles reduce R&D timelines and costs.

Gene editing evolution beyond CRISPR/Cas9 draws significant investment, with Mammoth Biosciences exploring novel Cas protein families, prime editing enabling more precise modifications, epigenetic editing allowing gene expression changes without DNA alterations, and base editing providing single nucleotide changes with high precision.

Lab automation and biofoundries receive major funding through Ginkgo Bioworks' $250M+ Google Cloud partnership for automated labs, Synonym Biotechnologies' standardized biomanufacturing facilities, and BenchSci's $69.9M Series D for AI-driven drug discovery automation. Foundation models for biology trained on large-scale biological datasets represent emerging investment opportunities as computational power intersects with biological data.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Who were the top-funded synbio startups in 2024, and how much did they raise?

• Generate Biomedicines: $273M Series C - AI-powered drug design platform using generative biology to create novel proteins and therapeutics
• Asimov: $175M Series B - Cell programming and genetic circuit design tools for precise biological system engineering
• Atlas Data Storage: $155M seed - DNA-based data storage technology spun off from Twist Bioscience
• Metagenomi: $100M Series B - Gene editing platform with reduced immune response for therapeutic applications
• BenchSci: $69.9M Series D - AI technology for drug discovery acceleration and laboratory automation
• Constructive Bio: $58M Series A - Synthetic genomics and novel biomolecule development

How much total funding has been invested into synthetic biology globally in 2024, and what does the trend look like for 2025 so far?

Global synthetic biology venture investment reached $12.2 billion in 2024, representing a significant recovery from the $6.9 billion recorded in 2023 (which marked a 31% decline from 2022's peak of $10.0 billion).

Total market valuations vary by methodology, with estimates ranging from $12.2 billion in pure venture investment to $20.01 billion in total market value when including public companies, strategic partnerships, and government funding. Strong Q4 2024 performance drove the annual growth trajectory.

The 2025 outlook shows robust confidence indicators through venture funding rebound continuation, IPO market revival with 16 biotech IPOs raising $3 billion in the first nine months of 2024, and increasing corporate venture capital participation across industries. Historical context shows 2024's performance exceeded the pandemic-driven 2021 surge of $7.8 billion.

Market confidence stems from AI integration accelerating R&D cycles while reducing development costs, improved regulatory frameworks for synthetic biology products, commercial validation as first-generation products prove market viability, and growing sustainability focus driving demand for bio-based alternatives across industrial applications.

We've Already Mapped This Market

From key figures to models and players, everything's already in one structured and beautiful deck, ready to download.

DOWNLOAD

If you need to-the-point data on this market, you can download our latest market pitch deck here

Which new or returning investors entered the space in 2025, and what does that suggest about confidence in the market?

Corporate venture capital arms expanded significantly in 2025, with traditional energy, agriculture, and chemical companies establishing dedicated synthetic biology investment programs, suggesting these industries recognize synbio as essential for future competitiveness rather than experimental technology.

Tech giants increased their synthetic biology allocations through both direct investments and strategic partnerships, with Google's $250M+ cloud partnership with Ginkgo Bioworks exemplifying how technology infrastructure providers view biological platforms as major growth opportunities requiring substantial computational resources.

International investors, particularly from Asia-Pacific regions, accelerated their entry into US and European synthetic biology markets, indicating global recognition of the sector's commercial potential and the desire to participate in platform technologies that will reshape manufacturing across industries.

The entry of traditional manufacturing and industrial companies through both direct investments and acquisition strategies demonstrates confidence that synthetic biology platforms will transition from research tools to commercial production capabilities, validating the sector's progression from laboratory curiosity to industrial reality.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Which synbio companies or verticals look most likely to attract funding in 2026, based on current signals?

AI-enabled platforms combining machine learning with biological design represent the highest-probability funding targets, particularly companies developing foundation models for biology, automated protein design, and metabolic pathway optimization that can accelerate traditional R&D timelines.

Biomanufacturing infrastructure companies appear positioned for substantial funding as the industry transitions from laboratory-scale to commercial production, with investors targeting scalable production facilities, automation technologies, and standardized bioprocessing platforms that can serve multiple applications.

Specialized healthcare applications, particularly in oncology, immunology, and neuroscience, attract investor attention due to high-value markets, clear regulatory pathways, and demonstrated corporate venture capital interest from pharmaceutical companies seeking novel therapeutic modalities and manufacturing capabilities.

Carbon capture and utilization technologies using synthetic biology approaches gain momentum as companies and governments prioritize sustainability metrics, creating investment opportunities in bio-based chemicals, sustainable materials, and renewable energy applications that address climate change while generating commercial returns.

What are the most promising ways for an investor or operator to enter or collaborate within this ecosystem today?

Investors should focus on AI-enabled platforms that combine machine learning with biological design, biomanufacturing infrastructure companies developing scalable production capabilities, and specialized applications in high-value markets like pharmaceuticals and specialty chemicals that offer clear commercial pathways.

Operators can leverage established platforms like Ginkgo Bioworks and Twist Bioscience for infrastructure access rather than building capabilities from scratch, focus on specific applications with well-defined markets and clear value propositions, and build strategic partnerships with pharmaceutical, chemical, or agricultural companies seeking synthetic biology solutions.

Corporate collaboration models include direct investment through corporate venture capital arms, strategic partnerships and joint ventures for specific applications, acquisition targets for technology integration, and R&D collaborations that combine corporate resources with startup innovation and agility.

Government support mechanisms provide additional entry points through SBIR/STTR grants for early-stage development, international funding programs supporting synthetic biology research, regulatory sandboxes for testing novel applications, and public-private partnerships that reduce risk while accelerating commercialization timelines.

Conclusion

Sources

1. SynBioBeta 2025 Investment Report
2. Scispot Top 20 Investors for Early Stage Industrial Bio Companies
3. CB Insights Synthetic Biology Startup Investors
4. Y Combinator Biotech Companies
5. Forbes Tech Titans Investing in Synthetic Biology
6. Ginkgo Bioworks JPM 2024 Presentation
7. Twist Bioscience Investor Relations
8. BCC Research Top Ten Suppliers Synthetic Biology Market
9. Persistence Market Research Top 10 Synthetic Biology Companies
10. Ahren Innovation Capital Constructive Series A
11. Investors Webinar Report 2024
12. Labiotech Pharma Biotech Venture Capital Arms
13. AddVentures CVC Peers in China
14. Grand View Research Synthetic Biology Market
15. Meticulous Research Synthetic Biology Market
16. Tidetron Bio Synthetic Biology Investment Explosion
17. CSIRO Synbio 2024 Progress Report
18. Science Direct Synthetic Biology Investment Trends
19. LinkedIn AI Synthetic Biology Market
20. Startup Ticker Myria Pre-Seed Round
21. Wellfound Synthetic Biology Startups
22. Securities.io Top Synthetic Biology Public Companies
23. Globe Newswire Synthetic Biology Market Size